- Exact Sciences (NASDAQ:EXAS) Q1 results ($M): Revenue: 162.0 (+79.4%).
- Net loss: (83.1) (-110.9%); loss/share: (0.66) (-100.0%).
- Cologuard test volume: 334K (+79%); average revenue/test: $483 (-0.04%); average cost/test: $128 (+3.2%).
- 2019 guidance: Revenue: $725M - 740M from $710M - 730M.
- Shares are down 3% after hours.
- Previously: EXACT Sciences beats by $0.07, beats on revenue (April 30)
Exact Sciences Q1 revenue up 79%; Cologuard volume up 79%
Recommended For You
About EXAS Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
EXAS | - | - |
Exact Sciences Corporation |